In Vitro Model of Coronary Angiogenesis
March 10th, 2020
7.9K views
In vitro models of coronary angiogenesis can be utilized for the discovery of the cellular and molecular mechanisms of coronary angiogenesis. In vitro explant cultures of sinus venosus and endocardium tissues show robust growth in response to VEGF-A and display a similar pattern of COUP-TFII expression as in vivo.
Overview
This study presents an in vitro model for investigating coronary angiogenesis using explant cultures of sinus venosus and endocardium tissues. The model effectively mimics in vivo conditions, allowing for the exploration of cellular responses to VEGF-A.
Key Study Components
Area of Science
- Neuroscience
- Cardiovascular Biology
- Cellular Biology
Background
- Coronary angiogenesis is crucial for heart development and repair.
- Understanding the mechanisms behind this process can lead to therapeutic advancements.
- In vitro models provide a controlled environment for detailed study.
- VEGF-A is a key factor in promoting angiogenesis.
Purpose of Study
- To develop a reliable in vitro model for studying coronary angiogenesis.
- To analyze the effects of VEGF-A on tissue growth and angiogenic sprouting.
- To investigate the expression patterns of COUP-TFII in response to angiogenic stimuli.
Methods Used
- Isolation of embryonic heart tissues from mice.
- Culture of sinus venosus and ventricles in a controlled environment.
- Treatment with VEGF-A to assess angiogenic response.
- Immunofluorescence microscopy to evaluate cellular changes.
Main Results
- VEGF-A treatment significantly increased the density and length of angiogenic sprouts.
- COUP-TFII expression was reduced as endothelial cells migrated.
- The model successfully mimicked in vivo angiogenesis processes.
- Endothelial sprouts from sinus venosus responded robustly to VEGF-A stimulation.
Conclusions
- The in vitro model is a valuable tool for studying coronary angiogenesis.
- VEGF-A plays a critical role in promoting angiogenic growth.
- Further research can explore therapeutic targets for cardiovascular diseases.
Frequently Asked Questions
What is the significance of this study?
This study provides insights into the mechanisms of coronary angiogenesis, which is vital for heart health.
How does VEGF-A influence angiogenesis?
VEGF-A promotes endothelial cell proliferation and migration, leading to the formation of new blood vessels.
What are the advantages of using an in vitro model?
In vitro models allow for controlled experimentation and detailed observation of cellular responses.
What tissues were used in the study?
Sinus venosus and endocardium tissues from embryonic mice were used for the explant cultures.
What techniques were employed to analyze the results?
Immunofluorescence microscopy was used to visualize and quantify angiogenic sprouts and protein expression.
Can this model be used for other studies?
Yes, this model can be adapted to study various aspects of cardiovascular biology and drug responses.
Executive Industry Relevance
This in vitro coronary angiogenesis model enables mechanistic de-risking of angiogenic targets by recapitulating VEGF-A-driven sprouting and COUP-TFII downregulation observed in vivo. It supports target validation and assay development for cardiovascular drug discovery by providing a reproducible, disease-relevant system to evaluate angiogenic responses. The model enhances predictive confidence in early discovery by allowing rapid, flexible interrogation of molecular mechanisms without in vivo constraints.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by modeling coronary vessel sprouting from defined progenitor tissues (sinus venosus and endocardium).
- Scientific Value: Validates target engagement through VEGF-A-induced angiogenic sprouting and COUP-TFII downregulation, mirroring in vivo mechanisms.
- Operational Value: Enables functional target de-risking via quantitative sprout length and density readouts under controlled conditions.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream screening by establishing baseline angiogenic capacity from sinus venosus and endocardium explants.
- Operational Value: Supports assay standardization through consistent sprouting metrics and VEGF-A dose-responsive outputs.
- Operational Value: Enhances screening readiness and platform reuse via reproducible culture inserts and measurable angiogenic endpoints.
Translational & Preclinical Research
- Scientific Value: Maintains disease relevance by modeling human coronary angiogenesis mechanisms using murine progenitor tissues with conserved VEGF-A signaling.
- Scientific Value: Provides translational continuity from discovery to preclinical validation by recapitulating key angiogenic biomarkers (COUP-TFII downregulation, VEGF-A responsiveness).
- Operational Value: Informs risk-adjusted advancement decisions through quantifiable angiogenic sprouting as a predictive readout for pathway modulation.
Pipeline & Workflow Integration
The model integrates into the discovery continuum from target hypothesis testing through lead identification to preclinical validation by providing mechanistic insights into angiogenic pathway modulation.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling direct observation of angiogenic sprouting from coronary progenitor tissues.
- Screening: Delivers assay readiness and quantitative outputs via VEGF-A-stimulated sprout formation, enabling compound effect comparison.
- Analytics: Generates measurable readouts (sprout length, density, COUP-TFII expression) that facilitate statistical comparison of angiogenic conditions.
- Translational Research: Connects to preclinical continuity through conserved angiogenic mechanisms and biomarker alignment (COUP-TFII, VEGF-A response).
- Enterprise Reuse: Functions as a reusable platform for angiogenic pathway assessment across multiple projects and target classes.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity in angiogenic signaling.
- Operational Value: Ensures standardization and reproducibility through defined explant culture protocols and VEGF-A response thresholds.
- Strategic Value: Improves go/no-go decisions by enabling early biological de-risking of angiogenic targets, reducing late-stage failure risk.
- Portfolio Impact: Supports risk-adjusted prioritization by providing quantitative angiogenic data to inform capital allocation and target advancement.
Implementation Considerations
- Requires expertise in embryonic tissue dissection, explant culture, and immunofluorescence microscopy.
- Dependent on sterile cell culture infrastructure, confocal imaging, and extracellular matrix coating capabilities.
- Necessitates cross-team standardization of explant isolation, culture timing, and VEGF-A treatment protocols.
- Involves adaptation considerations when extending to human iPSC-derived coronary progenitor cells or disease-model tissues.
- Limited by tissue availability and viability constraints of embryonic explants, which may affect scalability for high-throughput screening.
Biopharma FAQs
Why does COUP-TFII downregulation matter for target validation in angiogenesis?
COUP-TFII downregulation serves as a biomarker of venous-to-arterial endothelial transition during angiogenic sprouting, mirroring in vivo coronary angiogenesis. Its reduction in VEGF-stimulated sinus venosus cultures confirms mechanistic fidelity of the in vitro model to developmental angiogenesis. This readout enables target validation by linking molecular interventions to established angiogenic programs.
How does isolating sinus venosus and endocardium as independent variables support discovery pipeline goals?
Isolating sinus venosus and endocardium as independent variables allows researchers to attribute angiogenic responses specifically to these coronary progenitor tissues, eliminating confounding signals from other cardiac compartments. This variable isolation supports mechanistic de-risking by clarifying the cellular origin of VEGF-A-driven sprouting. It enhances target validation precision by enabling tissue-specific pathway interrogation in the discovery pipeline.
What quantitative dependent variable measurements enable angiogenic assessment in this model?
Quantitative measurements of angiogenic sprout length and density serve as dependent variables to assess VEGF-A-induced endothelial sprouting from sinus venosus and endocardium explants. These metrics provide objective, comparable readouts for evaluating angiogenic potency under experimental conditions. The near three-fold increase in sprout length with VEGF-A treatment demonstrates the model’s sensitivity to angiogenic stimulation.
Why do replication requirements matter for cross-functional collaboration in angiogenic studies?
Replication requirements ensure that angiogenic sprouting responses are consistent across experiments, enabling reliable data sharing between discovery, screening, and preclinical teams. Consistent replication validates the model’s robustness and supports standardized assay deployment across projects. This reproducibility is essential for cross-functional collaboration, as it builds confidence in angiogenic readouts used for target prioritization and lead selection.
What statistical analysis capabilities are required before implementing this angiogenic model in drug discovery workflows?
Implementation requires statistical capabilities to compare sprout length and density between control and treatment groups, such as t-tests or ANOVA, to determine significant angiogenic responses to VEGF-A or test compounds. These analyses enable objective assessment of compound effects on angiogenic sprouting, supporting data-driven go/no-go decisions. Statistical validation of VEGF-A responsiveness (e.g., significant sprout increase) is necessary to confirm assay suitability for screening applications.
Chapters in this video
0:04
Introduction
0:38
Embryo Harvesting
1:28
E11.5 Embryo Heart Isolation
2:14
Sinus Venosus (SV) and Ventricle Isolation
3:09
SV and Whole Ventricle Culture
4:09
Vascular Endothelial Growth Factor-A (VEGF-A) Treatment
4:54
Fixation, Immunostaining, Mounting, and Analysis
6:22
Results: Representative Coronary Angiogenesis Evaluation
7:12
Conclusion
